Clinical Trial Update: Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating veltuzumab and milatuzumab for relapsed or refractory B-cell non-Hodgkin lymphoma; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Milatuzumab (milatuzumab)
• Veltuzumab (veltuzumab)

Snippet

Sponsor: Beth Christian | Conditions: Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-02-06